Related Experiment Video
Updated: May 10, 2025
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Treatment Trends in Metastatic Renal Clear Cell Carcinoma in Argentina
Federico Cayol1, Gabriela Gatica2, Pablo Companys3
1Hospital Italiano de Buenos Aires, Ciudad De Buenos Aires, Argentina.
Purpose:
Renal cell carcinoma (RCC) accounts for 2%-3% of adult cancers globally. In Argentina, RCC is the fifth most common cancer, with over 2,000 new patients annually. This study aims to evaluate treatment trends for patients with metastatic renal cell carcinoma (mRCC) in Argentina.
Methods:
A retrospective study was conducted involving 689 patients with mRCC treated in Argentina between 2015 and 2022. The study analyzed treatment patterns and outcomes over time.
Results:
Access to combination treatments for mRCC in Argentina has increased significantly, with 87% of patients receiving such therapies during the 2021-2022 period. The real-world data demonstrated that combination treatments in this Latin American population resulted in prolonged progression-free survival and improved overall response rate.
Conclusion:
The results underscore the importance of ensuring access to combination therapies for patients with mRCC in Latin America. These findings should inform public health policies aimed at guaranteeing access to effective combination therapies.
